Individualizing Dosing of Irinotecan: Fig. 1.

Individualizing dosing of irinotecan.

Individualized drug dosing is a longstanding goal of clinical pharmacologists. Given the narrow therapeutic index of most anticancer agents, it is plausible that this approach would be of particular value in oncology. Irinotecan is an interesting agent for individualized dosing, given its complex metabolism and increasing knowledge of its pharmacokinetics predictors.

Alternative dosing schedules for irinotecan.

Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach attempts to maximize dose frequency and intensity by giving irinotecan every 2 weeks. A phase I trial of this approach is now complete and has led to a phase II trial in patien...

Fig. 1

Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD.

While anti-vascular endothelial growth factor (VEGF) therapy affords patients with neovascular age-related macular degeneration (AMD) a dramatically improved prognosis compared to all prior treatments, the chronic nature of the disease and the uncertainties regarding long-term dosing strategies represent important therapeutic challenges. Large randomized trials established the efficacy and safe...

Fig. 1: Mpeg-4 Coding Scheme

A programmable processor architecture for MPEG-4 video is proposed, that can serve as a coprocessor module in MPEG-4 decoder systems. It consists of a 64-bit dual-issue VLIW macroblock engine, a separate RISC core for bitstream parsing and system processing, and an autonomous I/O processor. A separate DSP is used for MPEG audio support. The architecture is fully programmable and supports parall...